New drug cocktail takes on superbugs in major trial
NCT ID NCT05905055
First seen Nov 06, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best current treatments for serious infections like urinary tract, kidney, lung, and abdominal infections caused by carbapenem-resistant bacteria. 126 adults participated. The goal was to see if the new combinations work better at curing the infection. This is a phase 3 trial, meaning it's a late-stage test before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLICATED INTRA-ABDOMINAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Meiji Research Site
Ankara, Turkey (Türkiye)
-
Meiji Research Site
Eskişehir, Turkey (Türkiye)
-
Meiji Research Site
Istanbul, Turkey (Türkiye)
-
Meiji Research Site
İzmit, Turkey (Türkiye)
-
Meiji Research Site
Trabzon, Turkey (Türkiye)
-
Meiji Research Site
Changsha, China
-
Meiji Research Site
Chongqing, China
-
Meiji Research Site
Fuyang, China
-
Meiji Research Site
Guangzhou, China
-
Meiji Research Site
Hangzhou, China
-
Meiji Research Site
Hefei, China
-
Meiji Research Site
Nanjing, China
-
Meiji Research Site
Nanning, China
-
Meiji Research Site
Quanzhou, China
-
Meiji Research Site
Shanghai, China
-
Meiji Research Site
Shenzhen, China
-
Meiji Research Site
Shijiazhuang, China
-
Meiji Research Site
Wuxi, China
-
Meiji Research Site
Xuzhou, China
-
Meiji Research Site
Zagreb, Croatia
-
Meiji Research Site
Kyjov, Czechia
-
Meiji Research Site
Limoges, France
-
Meiji Research Site
Nîmes, France
-
Meiji Research Site
Paris, France
-
Meiji Research Site
Strasbourg, France
-
Meiji Research Site
Kutaisi, Georgia
-
Meiji Research Site
Tbilisi, Georgia
-
Meiji Research Site
Zestaponi, Georgia
-
Meiji Research Site
Athens, Greece
-
Meiji Research Site
Be’er Ya‘aqov, Israel
-
Meiji Research Site
Ramat Gan, Israel
-
Meiji Research Site
Tel Aviv, Israel
-
Meiji Research Site
Nankoku, Kochi, Japan
-
Meiji Research Site
Hiroshima, Japan
-
Meiji Research Site
Kanazawa, Japan
-
Meiji Research Site
Nagasaki, Japan
-
Meiji Research Site
Nankoku, Japan
-
Meiji Research Site
Ōta-ku, Japan
-
Meiji Research Site
Shinjuku-ku, Japan
-
Meiji Research Site
Toyoake, Japan
-
Meiji Research Site
Daugavpils, Latvia
-
Meiji Research Site
Liepāja, Latvia
-
Meiji Research Site
Riga, Latvia
-
Meiji Research Site
Valmiera, Latvia
-
Meiji Research Site
Nitra, Slovakia
-
Meiji Research Site
Svidník, Slovakia
-
Meiji Research Site
Córdoba, Spain
-
Meiji Research Site
Madrid, Spain
-
Meiji Research Site
Kaohsiung City, Taiwan
-
Meiji Research Site
Taichung, Taiwan
-
Meiji Research Site
Taipei, Taiwan
-
Meiji Research Site
Bangkok, Thailand
-
Meiji Research Site
Chiang Mai, Thailand
-
Meiji Research Site
Khon Kaen, Thailand
Conditions
Explore the condition pages connected to this study.